191 related articles for article (PubMed ID: 9988833)
1. Risk of venous thromboembolism with third-generation oral contraceptives: A review.
Weiss G
Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 2):295-301. PubMed ID: 9988833
[TBL] [Abstract][Full Text] [Related]
2. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
3. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
4. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Winkler UH
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
[TBL] [Abstract][Full Text] [Related]
5. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
6. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
[TBL] [Abstract][Full Text] [Related]
7. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN; Slawson JG
J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
[No Abstract] [Full Text] [Related]
8. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
[TBL] [Abstract][Full Text] [Related]
9. Modern oral contraceptives and cardiovascular disease.
Rosenberg L; Palmer JR; Sands MI; Grimes D; Bergman U; Daling J; Mills A
Am J Obstet Gynecol; 1997 Sep; 177(3):707-15. PubMed ID: 9322646
[TBL] [Abstract][Full Text] [Related]
10. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
[TBL] [Abstract][Full Text] [Related]
11. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
12. [Third-generation oral contraceptives--how big is the risk of venous thrombosis?].
Iversen OE
Tidsskr Nor Laegeforen; 2004 Jun; 124(11):1521-2. PubMed ID: 15195157
[No Abstract] [Full Text] [Related]
13. The differential risk of oral contraceptives: the impact of full exposure history.
Lewis MA; MacRae KD; Kühl-Habichl D; Bruppacher R; Heinemann LA; Spitzer WO
Hum Reprod; 1999 Jun; 14(6):1493-9. PubMed ID: 10359554
[TBL] [Abstract][Full Text] [Related]
14. [Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations].
Milsom I; Odlind V; von Schoultz B; Ostlund I; Persson E
Lakartidningen; 2002 Jan; 99(1-2):10-2, 15. PubMed ID: 11871161
[No Abstract] [Full Text] [Related]
15. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
16. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill.
Black C; Kaye JA; Jick H
Br J Clin Pharmacol; 2002 Jun; 53(6):637-40. PubMed ID: 12047488
[TBL] [Abstract][Full Text] [Related]
17. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
Heinemann LA; Dinger JC; Assmann A; Minh TD
Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
Farmer RD; Lawrenson RA
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
[TBL] [Abstract][Full Text] [Related]
19. Newer oral contraceptives and the risk of venous thromboembolism.
Walker AM
Contraception; 1998 Mar; 57(3):169-81. PubMed ID: 9617533
[TBL] [Abstract][Full Text] [Related]
20. Oral contraceptives and venous thromboembolism.
Speroff L
Int J Gynaecol Obstet; 1996 Jul; 54(1):45-50. PubMed ID: 8842817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
